ADC Therapeutics SA
ADCT evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $157.0M
- Lead Asset:
- ADCT-601 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for ADCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADCT
ADC Therapeutics SA is a commercial-stage global pioneer in antibody-drug conjugates, with a marketed product ZYNLONTA and a pipeline of clinical-stage candidates, but faces negative shareholders' equity and regulatory uncertainty around full approval.
Key risk: Regulatory approval uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$157.0M
Cash Runway
—
Lead Asset
ADCT-601 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials · 1 FDA decision for ADC Therapeutics SA.
ADC Therapeutics SA is a commercial-stage global pioneer in antibody-drug conjugates, with a marketed product ZYNLONTA and a pipeline of clinical-stage candidates, but faces negative shareholders' equity and regulatory uncertainty around full approval.
- Commercial-stage global pioneer in antibody-drug conjugates (ADCs) [sec_mda · as of 2026-08-13]
- Marketed product ZYNLONTA (loncastuximab tesirine) for relapsed/refractory DLBCL [sec_mda · as of 2026-03-10]
- Cash & equivalents $219.1M as of 2026-06-30 [sec]
- Net income -$16.6M and shareholders' equity -$228.2M as of 2026-06-30 [sec]
- Key clinical trials: LOTIS-5 (Phase 3) and LOTIS-7 (Phase 1b) ongoing [sec · filed 2025-04-21]
What works
- Cash position of $219.1M as of 2026-06-30 provides substantial runway for ongoing operations and trials [sec]
- Completed enrollment for LOTIS-5 and initiated Part 2 of LOTIS-7, advancing key clinical programs [sec · filed 2025-04-21]
- Progressed four candidates to IND-enabling stage and identified two novel payloads, indicating pipeline depth [sec · filed 2025-04-21]
What to weigh
- Negative shareholders' equity of -$228.2M as of 2026-06-30 indicates accumulated losses exceed contributed capital [sec]
- Net loss of -$16.6M as of 2026-06-30 shows ongoing operating deficit [sec]
- Full regulatory approval for ZYNLONTA depends on LOTIS-5 data and FDA feedback, creating uncertainty [sec · filed 2026-06-24]
From the filings
Quoted directly from source documents.
Company is a commercial-stage global pioneer in ADCs
“ADC Therapeutics is a commercial-stage global pioneer in the field”
SEC MD&A · August 13, 2026
LOTIS-5 and LOTIS-7 trial progress
“LOTIS 5: Completed enrollment by end of year•LOTIS 7: Completed Part 1, dose escalation and initiated Part 2, does expansion”
SEC filings · April 21, 2025
Catalyst timeline
- 2020-09-16 · Phase3_Start: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5) — Initiation of pivotal Phase 3 trial for ZYNLONTA combination; data from this study is key for full regulatory approval.
- 2022-06-17 · Phase1_Start: A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) — Start of combination study exploring ZYNLONTA with other agents; Part 2 dose expansion is ongoing.
- 2023-07-28 · Phase1_Start: A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) — Pharmacokinetic and safety study in patients with hepatic impairment; may inform dosing and label.
Risks & what to watch (3)›
Key risks
- Regulatory approval uncertainty — Full approval for ZYNLONTA depends on LOTIS-5 data and FDA feedback; risk of losing accelerated approval [sec · filed 2026-06-24]
- Negative equity and net loss — Shareholders' equity -$228.2M and net loss -$16.6M as of 2026-06-30 indicate financial strain [sec]
- Clinical trial execution risk — LOTIS-5 and LOTIS-7 outcomes are pivotal; delays or negative data could impact pipeline [sec · filed 2025-04-21]
What to watch
- FDA feedback and sBLA submission for LOTIS-5 data to support full approval of ZYNLONTA [sec · filed 2026-06-24]
- LOTIS-7 Part 2 dose expansion results and any disclosed safety/efficacy data [sec · filed 2025-04-21]
- Progress of four IND-enabling candidates and two novel payloads into clinical development [sec · filed 2025-04-21]
- Cash runway and any further financing or business development transactions [sec · filed 2025-04-21]
Sources: Catalysts · SEC filings · SEC MD&A · Generated September 29, 2026 · How we verify sources →
Run ADC Therapeutics SA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ADC Therapeutics SA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$17M
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 4.8%
- Days to cover
- 6.1
- Shares short
- 5,144,704
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for ADC Therapeutics SA?
ADC Therapeutics SA is a commercial-stage global pioneer in antibody-drug conjugates, with a marketed product ZYNLONTA and a pipeline of clinical-stage candidates, but faces negative shareholders' equity and regulatory uncertainty around full approval.
What is ADC Therapeutics SA's lead drug candidate?
ADC Therapeutics SA's most advanced tracked candidate is ADCT-601 (Phase 1) for Evaluated in patients with sarcoma, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC).
Who is the CEO of ADC Therapeutics SA?
Dr. Ameet Mallik M.B.A., M.S. is the chief executive officer of ADC Therapeutics SA (ADCT).
Where is ADC Therapeutics SA headquartered?
ADC Therapeutics SA (ADCT) is headquartered in Epalinges, Switzerland.
What therapeutic areas does ADC Therapeutics SA focus on?
ADC Therapeutics SA develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.